UNSPSC 51385602: Aspirin

This classification denotes a cyclooxygenase inhibitor with the molecular formula C9H7O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E62HT5S2E9, and which bears US NIH Compound Identifier 23666729. Most nations schedule aspirin under HS 29182200 and SITC 51393. As of Q4 2014, ASPIRIN remains the US FDA Preferred Term for this commodity. Aspirin bears US NLM identifiers UMLS ID C0004057 and NCI Concept Code C287. SMILES: CC(=O)OC1=CC=CC=C1C(=O)[O-].

UNSPSC 51385602 Aspirin (Commodity) covers pharmaceutical products being procured by state and local health agencies, though recent solicitations under this code tag show limited direct aspirin purchasing and instead reflect broader pharmaceutical and over-the-counter product procurement across community health and state pharmacy benefit programs. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The scope of work encompasses supply of pharmaceutical and OTC products to support public health initiatives, with vendors typically required to maintain cGMP and FDA compliance, manage relationships with authorized wholesalers, provide detailed product data including NDC codes and pricing structures, and meet insurance and regulatory standards including the Drug Supply Chain Security Act.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline predates posting date, suggesting data inconsistency in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program before issuing formal competitive solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 with response deadline of March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for statewide and multi-state distribution through authorized wholesalers, with contract effectiveness July 1, 2026. MMCAP's evaluation weights price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of three authorized wholesalers and comply with specified pricing formats and administrative fee structures.